# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Paul Robeson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML048-SYN
- Date: 2026-06-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Theodore Bankole-Ashworth, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review of depression treatment. **S**

## History of present illness

Mr. Robeson returns three months after starting treatment. He has taken sertraline 200 mg each morning for five weeks, after two weeks at 150 mg, without missing doses and with only mild loose stools. He has attended every weekly behavioral activation session; the psychologist reports PHQ-9 scores in the high teens at each session, with no positive item 9. He walks most days but still has little pleasure, wakes at four, and has not sung or accepted any invitations. He has had no thoughts of suicide. He has had no elation or reduced need for sleep. **S**

| Element | Detail |
|---|---|
| Medicines | Sertraline 200 mg for five weeks after two weeks at 150 mg |
| Therapy | Eleven behavioral activation sessions |
| Mood | PHQ-9 17 from 22 |
| Safety | No thoughts of suicide |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; appetite back; weight 100.2 kg |
| Psychiatric | Positive | Little pleasure, early waking, low drive; no thoughts of suicide; no elation |
| Gastrointestinal | Positive | Mild loose stools on 200 mg |
| Cardiovascular | Negative | No palpitations |

4 systems reviewed. **S**

## Current medications

- Sertraline 100 mg tablet, one tablet each morning for one week, then stop **S**
- Venlafaxine extended-release 75 mg capsule, one capsule each morning with food **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/80 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 100.2 kg; BMI 27.8 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; PHQ-9: 17. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 137 mmol/L at this visit **S**
- PHQ-9: 22 at baseline, 17 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Weight 100.2 kg; blood pressure 128/80, pulse 74 |
| Psychiatric | Slowed; affect constricted; logical; no thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Recurrent major depression without response to sertraline** (F33.2). PHQ-9 22 to 17 after an adequate trial (five weeks at the maximum dose and twelve weeks in all): a 23 percent fall, short of a response. Sodium 137. Safety reviewed: no thoughts of suicide; medicines locked; 988 in his phone. Discussed with Dr. Lindqvist-Adebayo by phone: with no response rather than a partial one, switching to an SNRI is preferred over augmenting sertraline. ECT is not indicated now: there are no psychotic features, he is eating and drinking, and he is not acutely suicidal. **S**
   - Cross-taper: sertraline 100 mg for one week, then stop; venlafaxine extended-release 75 mg for one week, 150 mg for three weeks, then 225 mg.
   - Blood pressure at every visit on venlafaxine.
   - 30-day supplies, because venlafaxine is more dangerous than an SSRI in overdose; medicines stay locked.
   - Call for agitation, sweating, tremor or fever during the switch.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline and at least monthly during acute treatment (CMID) | Completed today | 17, down 23 percent from 22; item 9 scored 0 |
| Survey | PHQ-9 between visits, rated by the psychologist at each session | At each therapy session | Completed today | Rated at each session since the last visit; no positive item 9 reported |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis Lifeline | Every visit during active treatment | Completed today | No thoughts of suicide; medicines locked; safety plan reviewed |
| Laboratory | Sodium (SSRI or SNRI in an older adult) | Baseline, about four to six weeks after starting, and with symptoms | Completed today | 137 mmol/L, normal |
| Medication safety | Adequacy of the antidepressant trial (dose and duration) | At each review: at least four to eight weeks at an adequate dose before judging response | Completed today | Adequate trial: five weeks at 200 mg; no response; switch to venlafaxine |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | Every dose taken; mild loose stools |
| Medication safety | Switch safety: serotonin syndrome and discontinuation symptoms | During a cross-taper | Completed today | Warning signs explained; sertraline tapered over one week |
| Medication safety | Blood pressure (venlafaxine) | Baseline and at every visit on venlafaxine | Completed today | Baseline 128/80 before venlafaxine |
| Medication safety | Overdose risk and supply | With each prescription | Completed today | 30-day supplies; locked box |
| Medication safety | Watch for hypomania or mixed features after starting or changing an antidepressant | Every visit; repeat the MDQ if features emerge | Completed today | No signs of hypomania |
| Referral | Behavioral activation with a psychologist | Weekly for about sixteen sessions | Completed today | Eleven sessions; activity schedule continuing |
| Medication safety | ECT indications | At each review of a severe episode | Not indicated | No psychosis, refusal of food or drink, or acute suicidal risk; revisit if a second trial fails |
| Referral | Social work for income and costs | Monthly | Completed today | Monthly meetings continue |

## Goal progress

- Response to treatment: PHQ-9 down by at least half from 22. In progress; target 2026-10-05. **S**
- Remission: PHQ-9 below 5. In progress; target 2026-10-05. **S**
- Stay safe: safety plan in place and reviewed at every visit, with no self-harm. In progress; target 2026-10-05. **S**
- Sing again: daily vocal practice and one public engagement a month. In progress; target 2026-10-05. **S**
- Sleep six to seven hours a night. In progress; target 2026-10-05. **S**

## Medication changes

- Started: Sertraline 100 mg tablet, one tablet each morning for one week, then stop **S**
- Started: Venlafaxine extended-release 75 mg capsule, one capsule each morning with food **S**

## Guideline basis

- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), U.S. Department of Veterans Affairs and Department of Defense
- The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001), American Psychiatric Association
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), U.S. Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse phone check at one week of the switch. Review at about eleven weeks on venlafaxine with the PHQ-9, sodium and blood pressure. Weekly behavioral activation. Call or text 988 at any time in a crisis. **S**
- Next scheduled visit 2026-08-24: twenty-four-week review: partial response to venlafaxine; treatment-resistant depression; aripiprazole augmentation and an informed consent discussion about ECT. **S**
